Andrew Adler

Andrew Adler is a Principal Scientist at Novo Nordisk since December 2022, with previous experience as a Senior Scientist at Neurona Therapeutics, focusing on the clinical and pre-clinical investigation of inhibitory neuron transplants for treating temporal lobe epilepsy. Prior to this role, Andrew served as a Postdoctoral Scholar at Lund University and the University of California, San Diego, where significant work included tracing inputs to dopaminergic grafts in Parkinson's disease models and mapping inputs to graft-derived neurons following spinal cord injury. Andrew's early career includes an Engineering Internship at Medtronic, developing testing systems for drug infusion pumps. Andrew Adler holds a Ph.D. in Bioengineering and Biomedical Engineering from Duke University and a Bachelor's Degree in the same field from Northwestern University.